tiprankstipranks

MiMedx reports Q1 adjusted EPS 6c, consensus 5c

Reports Q1 revenue $88.21M, consensus $86.32M. Joseph Capper, MiMedx (MDXG) CEO, commented, “Our solid first quarter 2025 results include total net sales growth of 4% year-over-year and an Adjusted EBITDA margin of 20%. Our Surgical products recorded double-digit growth during the quarter, and we are continuing to see our efforts to build a compelling body of clinical evidence in this space unlock sizable opportunities for our products.”

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1